The Fourth Wave: Why America's Stimulant-Fentanyl Crisis Demands a New Treatment Playbook

The face of America's overdose epidemic is shifting again. And for the first time in years, the strategies that have saved thousands of lives may not be enough.

For over a decade, opioids have dominated public health conversations about addiction. Naloxone distribution, medication-assisted treatment, harm reduction sites—all were designed to combat heroin and prescription painkillers, then adapted for the synthetic opioid wave that followed.

But a new crisis is accelerating beneath the surface: stimulants laced with fentanyl are killing people who never intended to use opioids at all. And the treatment infrastructure built to respond to opioid use disorder is proving inadequate for this emerging threat.

A comprehensive analysis published February 27, 2026, in Frontiers in Psychiatry argues that urgent, multifaceted intervention is needed to address what researchers are now calling the "fourth wave" of the overdose epidemic—one characterized by the contamination of cocaine and methamphetamine with synthetic opioids, coupled with intentional polysubstance use that's proving deadlier than ever.

When Cocaine Becomes Russian Roulette

Estimates suggest that between 5.9% and 15% of unregulated stimulant samples now contain fentanyl. In the Northeast, cocaine has been the most commonly co-involved substance with fentanyl in overdose deaths since 2019. Connecticut alone saw a 9.3% increase in cocaine-related deaths between 2021 and 2022.

The numbers speak to something darker than statistics: people buying what they believe to be cocaine or methamphetamine are unknowingly gambling with their lives every time they use.

"Due to unregulated drug supplies, the risk of encountering synthetic opioid adulterants and unintentional overdose is growing for people who use unregulated or unprescribed stimulants," the study authors write.

At the same time, intentional stimulant use is surging. Methamphetamine use increased 43% over four years, from 2015 to 2019. Between 2021 and 2022, the prevalence of stimulant use jumped from 9.4 million to 10.2 million Americans—an 8.63% increase in a single year.

Perhaps most alarmingly, methamphetamine use disorder among Black Americans increased tenfold over the four-year period ending in 2019. This shift reflects broader racial disparities that have defined the fourth wave: starting around 2020, the rise in overdose mortality has disproportionately impacted Black and American Indian/Alaska Native populations.

The Treatment Gap

Here's the challenge facing addiction medicine: there are no FDA-approved medications for stimulant use disorder.

While opioid use disorder can be treated with buprenorphine, methadone, or naltrexone—all proven to reduce overdose risk—people struggling with cocaine or methamphetamine addiction have no comparable pharmaceutical tools. Some off-label medications like bupropion, topiramate, and mirtazapine have shown modest benefit. Long-acting psychostimulants demonstrate mixed evidence, particularly for cocaine use disorder, though they require careful monitoring.

But the single most effective intervention for stimulant use disorder isn't a pill.

It's contingency management.

Paying People to Get Better

Contingency management involves delivering tangible rewards—gift cards, vouchers, small prizes—in exchange for proof of abstinence from stimulants, typically through negative urine tests.

The concept makes some people uncomfortable. It can sound transactional, even mercenary. Paying people not to use drugs feels counterintuitive to a treatment culture built on willpower and accountability.

Yet decades of randomized controlled trials have demonstrated that contingency management works better than nearly any other intervention for stimulant use disorder, either alone or combined with pharmacotherapy.

"CM has demonstrated promising evidence for StUD treatment and thereby carries the potential to mitigate overdose risk in the fourth wave of the opioid epidemic," the study authors note.

Despite this overwhelming evidence, adoption remains minimal. Outside the VA system, very few U.S. institutions have implemented contingency management programs. Healthcare professionals remain largely unaware of it as a viable treatment option. Barriers include insurance coverage limitations, regulatory obstacles, and funding restrictions.

California is currently the only state with federal approval to include contingency management in its Medicaid program—where it's been rebranded as "Recovery Incentives Programs." All other states face a $75-per-participant cap, far below the threshold needed to sustain effective programs.

Organizations delivering contingency management span addiction treatment centers, hospitals, community health clinics, corrections facilities, and occasionally fire departments. But the infrastructure remains fragmented, underfunded, and dramatically underutilized.

Culture, Community, and Equity

Scaling contingency management isn't just a matter of funding—it requires careful attention to equity and cultural adaptation.

"If not carefully designed through an equity lens, there remains a potential for inequitable CM implementation," the study warns.

Programs must be developed with input from people with lived experience and designed around dignity, autonomy, and acknowledgment of real-world barriers to participation. Cultural adaptation has proven critical in American Indian and Alaska Native populations with alcohol use disorder, where appropriately tailored contingency management resulted in increased treatment participation and sustainability.

But literature on cultural adaptations specifically for stimulant use disorders remains sparse.

The researchers argue that effective treatment must incorporate structural competency education—training that helps healthcare professionals understand the systemic upstream forces influencing health outcomes, reduce implicit bias, and work from an equity-based perspective.

This becomes particularly important given documented disparities in care. White Americans are more likely to be legally prescribed medications for pain and opioid use disorder, while minoritized people must more often resort to illicit or unregulated sources, increasing exposure to contaminated drug supplies.

"These treatment disparities often arise from stigma and implicit bias, manifested as inaccurate beliefs that minoritized people have higher pain tolerance," the study notes.

Beyond Abstinence

The analysis also calls for rethinking what treatment success looks like.

Measuring abstinence alone may overlook improvements in other critical domains: reductions in higher-risk behaviors like solitary use or injection; increases in behaviors that reduce overdose risk, such as carrying naloxone; and overall improvements in quality of life.

Harm reduction approaches remain essential. The researchers emphasize expanding access to drug-checking services that detect adulterant presence and levels, allowing people to make informed decisions about use, safety protocols, and dosage. Test strips for fentanyl and xylazine can help people who use stimulants avoid unintentional opioid exposure.

Routine naloxone distribution to people who use stimulants—encouraged by the CDC and professional clinical guidelines—acknowledges the reality of contaminated drug supplies. Even those who don't use opioids intentionally need access to overdose reversal medication.

For people with co-occurring stimulant use disorder and opioid use disorder, medications like buprenorphine and methadone can reduce overdose risk, though evidence on effectiveness for this population remains limited.

What Happens Next

The study authors make clear that the current wave of the overdose epidemic demands more than incremental adjustments to existing programs.

"Multilevel approaches are needed to address the escalating overdose epidemic among people who use stimulants, especially considering the disproportionate effect of the overdose crisis on historically minoritized communities," they write.

This means prioritizing multisectoral and interdisciplinary collaboration. Community awareness campaigns. Policy and institutional reforms. Structural competency training. Family and community engagement in recovery journeys.

It also means confronting uncomfortable truths about why effective interventions like contingency management remain sidelined. Regulatory barriers can be changed. Funding can be allocated. Cultural adaptations can be developed.

The question is whether public health infrastructure will respond with the urgency this moment demands—or whether the fourth wave will claim thousands more lives while effective treatments remain locked behind bureaucratic inertia.

The contamination of stimulant supplies with fentanyl means people who never intended to use opioids are dying of opioid overdoses. Traditional harm reduction tools can help. But without pharmaceutical treatments for stimulant use disorder, without widespread access to contingency management, and without culturally adapted interventions that reach minoritized communities, the death toll will continue to rise.

The researchers' call to action is unambiguous: adapt, scale, and implement evidence-based approaches with equity at the center. Anything less is a choice to let people die from a crisis we already know how to address.